

EISAI CO. LTD.

ISIN: JP3160400002 WKN: 4523 Asset Class: Stock



Company Profile

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

Financial figures, Fiscal year: from 01.04. to 31.03.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	621,847,000,000		640,260,000,000		517,886,000,000	
Common stock capital		44,986,000,000		44,986,000,000		44,986,000,000
Fixed assets	641,503,000,000		599,055,000,000		572,123,000,000	
Equity capital of a company		822,571,000,000		771,533,000,000		727,942,000,000
Cash and cash equivalents	267,350,000,000		309,633,000,000		248,740,000,000	
Accrued liabilities		1,299,000,000		1,473,000,000		10,164,000,000
Other assets	-		-		-	
Current liabilities		298,945,000,000		313,333,000,000		256,017,000,000
Prepayments and accrued income		-		-		-
Non-current liabilities		141,834,000,000		154,448,000,000		106,050,000,000
Different income		-		-		-
Other liabilities		19,096,000,000		19,407,000,000		4,092,000,000
Total assets	1,263,350,000,000	1,263,350,000,000	1,239,315,000,000	1,239,315,000,000	1,090,009,000,000	1,090,009,000,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	11,076	11,322	11,237
Equity ratio	66.90%	64.09%	69.05%
Debt-equity ratio	49.48%	56.04%	44.81%

Others

	2023	2022	2021
Tax Expense Rate	-26.27%	16.05%	19.16%

EISAI CO. LTD.

ISIN: JP3160400002 WKN: 4523 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	744,402,000,000	756,226,000,000	645,942,000,000
Net income	55,432,000,000	47,954,000,000	42,119,000,000
EBIT	255,930,000	326,802,000	314,658,000
Operating income before taxes	45,012,000,000	54,458,000,000	52,551,000,000
Cash Flow	-1,772,000,000	117,590,000,000	73,853,000,000
Net interest income	2,357,000,000	-9,000,000	108,000,000
Research and development expenses	156,691,000,000	158,030,000,000	138,822,000,000
Income taxes	-11,824,000,000	8,741,000,000	10,068,000,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	403,251	400,756	344,901

Board of Directors

Clive Thornley	Member of Supervisory Board
Fumihiko Ike	Member of Supervisory Board
Hideki Hayashi	Member of Supervisory Board
Hideyo Uchiyama	Member of Supervisory Board
Hiroyuki Kato	Member of Supervisory Board
Ryota Miura	Member of Supervisory Board
Toru Moriyama	Member of Supervisory Board
Yoshiteru Kato	Member of Supervisory Board
Yuko Yasuda	Member of Supervisory Board
Yumiko Miwa	Member of Supervisory Board

Members of Management Board

Haruo Naito	Chairman of Managing Board
Akiko Nakahama	Member of Executive Committee
Gary Hendler	Member of Executive Committee
Ivan Cheung	Member of Executive Committee
Kazuhiko Tamura	Member of Executive Committee
Keisuke Naito	Member of Executive Committee
Kenta Takahashi	Member of Executive Committee
Lynn Kramer	Member of Executive Committee
Masatomi Akana	Member of Executive Committee
Mitsuo Kosaka	Member of Executive Committee
Mitsuru Shomon	Member of Executive Committee
Sayoko Sasaki	Member of Executive Committee
Shin Ujiie	Member of Executive Committee
Shohei Kanazawa	Member of Executive Committee
Takashi Owa	Member of Executive Committee
Tatsuyuki Yasuno	Member of Executive Committee
Terushige Iike	Member of Executive Committee
Teruyuki Masaka	Member of Executive Committee
Toshitaka Asano	Member of Executive Committee
Yanhui Feng	Member of Executive Committee
Yasushi Okada	Member of Executive Committee